Zydus Lifesciences gets FDA final approval for Ofirmev generic

Zydus Lifesciences gets FDA final approval for Ofirmev generic — Acetaminophen Injection
Zydus Lifesciences gets FDA final approval for Ofirmev generic — Acetaminophen Injection. Photo courtesy of Zydus Cadila.

Zydus Lifesciences Limited (formerly Cadila Healthcare) said that it has secured final approval from the US Food and Drug Administration (FDA) for Acetaminophen Injection, 1,000 mg/100 mL (10 mg/mL) single-dose vials.

The product is the generic of Ofirmev. It is approved for easing mild to moderate pain and bringing down fever. Ofirmev also has the approval to be used in combination with opioid (narcotic) drugs for relieving pain that is at moderate to severe levels.

Zydus Lifesciences will manufacture Acetaminophen Injection at its injectable manufacturing plant in Jarod, near Vadodara.

Zydus Lifesciences gets FDA final approval for Ofirmev generic — Acetaminophen Injection
Zydus Lifesciences gets FDA final approval for Ofirmev generic — Acetaminophen Injection. Photo courtesy of Zydus Cadila.

According to IQVIA MAT Aug 2022, Acetaminophen injection had sales of $72 million in the US.

Zydus Lifesciences said that it currently has 330 approvals and to date filed more than 428 abbreviated new drug applications (ANDAs) since the start of the filing process in FY 2003-04.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Total
0
Shares
Related Posts
Read More

Amgen to acquire Celgene psoriasis drug Otezla for $13.4bn

Amgen acquisition of Otezla : Amgen has agreed to acquire global rights to Celgene’s psoriasis drug Otezla (apremilast) for $13.4 billion, which includes $2.2 billion in expected future cash tax benefits. The deal is being executed to pave way for regulatory approval for the previously announced Bristol-Myers Squibb acquisition of Celgene in a deal worth […]

The post Amgen to acquire Celgene psoriasis drug Otezla for $13.4bn appeared first on PharmaNewsDaily.com.